Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pluristem Initiates Phase-I CLI Trial
Pluristem has enrolled the first patient in a phase-I clinical trial of allogeneic placental-derived adherent stromal cell product, termed as PLX-PAD. PLX-PAD is to be used in patients
Pluristem has enrolled the first patient in a phase-I clinical trial of allogeneic placental-derived adherent stromal cell product, termed as PLX-PAD. PLX-PAD is to be used in patients
Mylan has announced that its subsidiary Mylan has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50mg. Bicalutamide Tablets are the
Lundbeck and LifeHealth have entered into a definitive agreement under which Lundbeck acquires all shares of LifeHealth, the holder of Xenazine rights. The deal is an all-cash transaction
Neugenesis has collaborated with PATH to develop an influenza vaccine production system. Under the agreement, Neugenesis would conduct proof of concept work to demonstrate the utility of the
Lundbeck acquires Aarhus-based biotech company NeuronIcon and its technologies. At the same time, Lundbeck has signed a collaborative agreement with the University of Arhus on additional neurology research.
iMedicor has collaborated with Medical Missions for Children (MMC) to distribute their Global Video Library of Medicine worldwide, using streaming video via internet. A final agreement between the
BG Medicine and Humana have enrolled 6,822 Humana members, in a study intended to develop new diagnostics for predicting heart attacks and strokes in months or years before
Amgen’ phase-III trial evaluating denosumab versus Zometa (zoledronic acid) for bone metastases in 2,049 patients with advanced breast cancer, has met its primary and secondary endpoints. The trial
Absorption Systems has acquired Perry Scientific, an in-vivo toxicology and pharmacokinetics testing company, located in San Diego, California. Patrick Dentinger, President and CEO of Absorption Systems, said: “The
GTx has initiated Phase I multiple ascending dose clinical trial evaluating GTx-758, an oral LH inhibitor for first line treatment of advanced prostate cancer. A Phase I single